U.S. Bancorp notched a rise in earnings for the latest quarter as it benefited from a lower loan-loss provision and growth in fee income. The healthcare-products maker trimmed and narrowed its ...

In July 2025, global markets have been navigating a complex landscape marked by new U.S. tariff announcements and mixed economic signals, with the Nasdaq Composite Index showing resilience amidst ...

These are two ASX favourites to watch closely this month. The post Will these ASX 100 shares surge or sink in July? appeared first on The Motley Fool Australia.

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...

Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

The first half of 2025 was a roller-coaster ride for investors with the broader market surging to new highs at the beginning ...

After a 12-month decline, CSL Ltd (ASX: CSL) shares look well-placed to rocket 26% heading into 2026. Here’s why.

Real-time index price for Nasdaq Biotechnology Index (NBI), along with buy or sell indicators, analysis, charts, historical performance, news and more ...